Compare Quest Diagnostics Inc (DGX) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M). The key difference: Quest Diagnostics Inc is far larger — about 34.1× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Rex Fang & Innovation Equity Premium Income ETF for 56 Days on average.
| DGX | FEPI | |
|---|---|---|
Market Cap | $25.48B | $746.48M |
Volume | 941,866 | 334,337 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $49.54 |
52-Week Low | $173.49 | $37.98 |
Typical Hold Time | 56 Days | 56 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
FEPI trades at $43.51, down 0.18% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF employs a covered call strategy on AI and tech stocks, generating high weekly dividends but facing capped upside. Recent news highlights its 25% yield but notes underperformance versus peers in total return.
The outlook is mixed: high income appeals, but concentration in volatile tech and covered call limitations pose risks. Investors seeking yield may find value, yet must weigh potential underperformance if tech momentum slows. Risks include sector volatility and strategy constraints in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
